Clinical and prognostic implications of C-reactive protein levels in myocardial infarction with nonobstructive coronary arteries

Kai M Eggers MD, PhD1 | Tomasz Baron MD, PhD1 | Marcus Hjort MD1 | Anna M Nordenskjöld MD, PhD2 | Per Tornvall MD, PhD3 | Bertil Lindahl MD, PhD1

1Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
2Faculty of Health, Department of Cardiology, Örebro University, Örebro, Sweden
3Department of Clinical Science and Education, Södersjukhuset, Karolinska Institute, Stockholm, Sweden

Abstract

Background: Myocardial infarction with nonobstructive coronary arteries (MINOCA) is a heterogeneous condition. Recent studies suggest that MINOCA patients may have a proinflammatory disposition. The role of inflammation in MINOCA may thus be distinct to myocardial infarction with significant coronary artery disease (MI-CAD).

Hypothesis: We hypothesized that inflammation reflected by C-reactive protein (CRP) levels might carry unique clinical information in MINOCA.

Methods: This retrospective registry-based cohort study (SWEDEHEART) included 9916 patients with MINOCA and 97,970 MI-CAD patients, used for comparisons. Multivariable-adjusted regressions were applied to investigate the associations of CRP levels with clinical variables, all-cause mortality and major cardiovascular events (MACE) during a median follow-up of up to 5.3 years.

Results: Median admission CRP levels in patients with MINOCA and MI-CAD were 5.0 (interquartile range 2.0–9.0) mg/dl and 5.0 (interquartile range 2.1–10.0 mg/dl), respectively. CRP levels in MINOCA exhibited independent associations with various cardiovascular risk factors, comorbidities and estimates of myocardial damage. The association of CRP with peripheral artery disease tended to be stronger compared to MI-CAD. The associations with female sex, renal dysfunction and myocardial damage were stronger in MI-CAD. CRP independently predicted all-cause mortality in MINOCA (hazard ratio 1.22 [95% confidence interval 1.17–1.26]), similar to MI-CAD (p interaction = 0.904). CRP also predicted MACE (hazard ratio 1.08 [95% confidence interval 1.04–1.12]) but this association was weaker compared to MI-CAD (p interaction < 0.001).

Conclusions: We found no evidence indicating the presence of a specific inflammatory pattern in acute MINOCA compared to MI-CAD. However, CRP levels were independently, albeit moderately associated with adverse outcome.

Keywords: C-reactive protein, inflammation, MINOCA, myocardial infarction, prognosis
1 | INTRODUCTION

Myocardial infarction with nonobstructive coronary arteries (MINOCA) is a condition that is gaining increasing interest.1,2 The term MINOCA refers to a myocardial infarction (MI) fulfilling the criteria outlined in the Universal Definition3 but without coronary stenosis ≥50%. Around 5%–10% of all MI are MINOCA.4 The etiology of MINOCA is heterogenous with a multitude of causative or contributing mechanisms.1 However, recent studies suggest that MINOCA patients as well may be charaterized by a proinflammatory disposition in terms of more common inflammatory disorders5,6 or as reflected by circulating biomarkers.7

Inflammation also represents a key pathobiological mechanism in acute coronary syndromes. C-reactive protein (CRP), a sensitive downstream marker of the inflammation cascade, has been linked in acute coronary syndromes. C-reactive protein (CRP), a sensitive downstream marker of the inflammation cascade, has been linked in acute coronary syndromes. C-reactive protein (CRP), a sensitive downstream marker of the inflammation cascade, has been linked in acute coronary syndromes.

The aims of the present study were to closer investigate the associations of CRP levels in MINOCA with clinical findings and outcome overall, and in comparison to CRP levels in MI-CAD. For this purpose, a large cohort of Swedish MI patients with data available in the SWEDHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) registry was assessed.

2 | METHODS

2.1 | Study population

This study is part of the TOTAL-AMI (Tailoring Of Treatment in All comers with Acute Myocardial Infarction) project. The primary aim of TOTAL-AMI is to study the mechanisms and implications of different MI subtypes5 and of comorbidities (e.g. chronic obstructive pulmonary disease, atrial fibrillation, renal dysfunction) in MI. TOTAL-AMI uses data from SWEDHEART which is a Swedish registry collecting information from consecutive patients admitted to coronary care units or other specialized facilities because of suspected acute coronary syndrome. SWEDHEART provides almost nationwide coverage and lifelong follow-up. Upon hospital admission, patients receive written information about the registry, have the right to deny participation and to get their data erased upon request. Written informed consent is not required according to Swedish law.

The population for the present study included all MI patients, admitted between January 2005 and May 2018, with available data for levels of CRP. Only first-time admissions were considered. To be regarded having MINOCA, MI patients were required to have normal or near-normal coronary arteries (<50% stenosis), to be free from a history of MI or coronary intervention and not to have undergone a coronary intervention during the index hospitalization. MI patients with significant (≥50%) coronary stenoses were regarded having MI-CAD. MI-CAD patients with a history of MI or coronary intervention were excluded from the analyses to avoid the confounding impact of pre-existing coronary artery disease in comparisons with MINOCA patients.

All data had been made pseudonymized before the statistical analyses. The study was conducted according to the principles of the 1975 Declaration of Helsinki and had been approved by the Regional Ethical Review Board in Stockholm (2012/60–31/2).

2.2 | Measurement of CRP levels

The CRP levels used in this analysis had been obtained upon admission as part of clinical routine practice in Sweden. Measurements were performed using standard assays at the central laboratories of the respective hospitals participating in SWEDHEART.

2.3 | Prognostic evaluation

Information on patient outcome was obtained by merging SWEDHEART with data from the mandatory Swedish Patient Registry (hospitalization dates and discharge diagnoses based on International Classification of Diseases, 10th revision, Clinical Modification [ICD-10-CM] codes) and the Swedish Cause of Death Registry, both held by the Swedish Board of Health and Welfare. The outcomes considered for this analysis were all-cause mortality with available data until May 2018 and major cardiovascular adverse events (MACE), defined as the composite of cardiovascular mortality, readmissions for recurrent MI (ICD-10-CM code I21), hospitalization for heart failure (ICD-10-CM code I50) and ischemic stroke (ICD-10-CM code I63). During the first 30 days after the index hospitalization, it is not possible to separate a new MI from the index MI in the Patient Registry. Therefore, only MI occurring at least 30 days after the hospitalization were counted to avoid ‘contamination’ from the index event. Information on MACE was only available until December 2017 since there is a time lag for processing hospitalization data within the Swedish Patient Registry.

2.4 | Statistical analysis

All continuous variables were skewed and are reported as medians with interquartile ranges (IQR). Differences were tested using the Pearson χ² test. Categorical variables are expressed as frequencies and percentages with differences being assessed using the Kruskal-Wallis test.

Multiple linear regressions were used to investigate the associations of CRP levels with clinical variables in MINOCA and MI-CAD, respectively. Model 1 included age, sex, current smoking, hypertension, diabetes mellitus, hyperlipidemia, estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration equation),
previous heart failure, previous stroke, peripheral artery disease, chronic obstructive pulmonary disease, previous or present cancer, dementia and atrial fibrillation on the admission ECG. In addition, adjustment was made for medications on admission (antiplatelets, betablockers, inhibitors of the renin-angiotensin-aldosterone system [angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers] and statins), admission year and hospital. In model 2, previous heart failure was replaced by left-ventricular ejection fraction estimated by in-hospital echocardiography. Model 3 was adjusted as model 1 with addition of high-sensitivity cardiac troponin T (hs-cTnT) as covariate. Values of CRP and hs-cTnT were highly skewed and ln-transformed in all analyses to achieve normality.

The associations of CRP (ln) with adverse events were studied with the use of Cox regression models. We applied a similar adjustment set as for the multiple linear regressions including ST-segment changes on the admission ECG but without considering medications upon admission. The prognostic implications of CRP (ln) relative to the MI type (MINOCA vs. MI-CAD) were assessed by forcing an interaction term CRP (ln)*MI type into model 1 with additional adjustment for in-hospital coronary revascularization. Prognostic estimates are presented as hazard ratios (HR) with 95% confidence intervals (CI). Cumulative probability curves were constructed using the Kaplan–Meier method, and the log-rank test was used to compare the occurrence of adverse outcome across CRP quartiles.

In all tests, a two-sided p value <.05 was considered significant. The software package SPSS 27.0 (SPSS Inc., Chicago, IL) was used for the analyses.

3 | RESULTS

The MINOCA cohort investigated in the present analysis consisted of 9916 patients. Out of totally 125,713 MI-CAD patients in the dataset, 97,970 (77.9%) had no history of coronary revascularization or MI and were used for comparative analyses.

The median CRP levels were 5.0 (IQR 2.0–9.0) mg/dl in MINOCA and 5.0 (IQR 2.1–10.0) mg/dl in MI-CAD. Information on clinical characteristics in MINOCA patients in relation to CRP quartiles is presented in Table 1. Increasing CRP quartiles exhibited significant associations across many cardiovascular risk factors and comorbidities, apart from hyperlipidemia and previous stroke. Increasing CRP quartiles were also associated with more adverse ECG findings, poorer left-ventricular ejection fraction and higher hs-cTnT levels. The clinical characteristics of MI-CAD patients are presented in the Table S1.

Upon multivariable adjustment, significant and consistent associations were noted between CRP (ln) and current smoking, diabetes mellitus, lower glomerular filtration rate, estimates of myocardial damage (i.e. lower left-ventricular ejection fraction and higher hs-cTnT levels), peripheral artery disease, chronic obstructive pulmonary disease, previous or present cancer and atrial fibrillation (Table 2). As illustrated by the non-overlapping 95% confidence intervals of the regression coefficients in model 2, the association of CRP (ln) with peripheral artery disease tended to be stronger in MINOCA compared to MI-CAD, and there was a trend towards a stronger association with chronic obstructive pulmonary disease (Table S2B). Among patients with MI-CAD, CRP (ln) exhibited stronger associations with female sex, lower glomerular filtration rate and depressed left-ventricular ejection fraction (Table S2B). Even the extent of coronary artery disease (categorized as 1- or 2-vessel disease, 3-vessel or left main disease, inconclusive angiographic findings) was associated with CRP (ln) in MI-CAD when added as additional variable to model 2 (β = 0.041; p < .001).

During a median follow-up of 5.3 (2.3–8.6) years, 1854 (18.7%) MINOCA patients died. Totally 1939 (20.1%) MINOCA patients suffered a MACE during a median follow-up of 4.2 (1.5–7.6) years. Increasing CRP quartiles were significantly associated with both outcomes with continuously diverging Kaplan–Meier curves, in particular for patients in the top vs. the lower three CRP quartiles (Table 1; Figures 1(A),(B)). The associations of CRP quartiles with MACE were mainly driven by higher rates of mortality and hospitalizations for heart failure (Table 1). The multivariable-adjusted HR of CRP (ln) were 1.21 (95% CI 1.17–1.26) regarding all-cause mortality and 1.08 (95% CI 1.04–1.12) regarding MACE (Table 3). Further adjustments for left-ventricular ejection fraction or hs-cTnT (ln) did not alter these associations. The corresponding HR in MI-CAD patients were 1.22 (95% CI 1.20–1.23) regarding all-cause mortality and 1.17 (95% CI 1.16–1.18) regarding MACE. The interactions of the type of MI (MINOCA vs. MI-CAD) on the associations of CRP (ln) were non-significant regarding all-cause mortality but reached significance regarding MACE.

4 | DISCUSSION

In the present analysis investigating a large cohort of MINOCA patients, CRP levels yielded moderate but independent prognostic information. Increases of one standard deviation in ln-transformed CRP levels were associated with 21–23% risk increases regarding all-cause mortality and 8–9% risk increases regarding MACE in models considering cardiovascular risk factors, comorbidities and estimates of myocardial damage.

However, contrasting to our hypothesis, CRP levels did not provide unique prognostic information compared to patients with MI-CAD. The prognostic value of CRP was similar for MINOCA and MI-CAD patients regarding all-cause mortality, and its magnitude regarding MACE was relatively lower in MINOCA patients compared to those with MI-CAD. This is likely explained by the fact that CRP levels in MI at least in part reflect an acute-phase reaction resulting from myocardial necrosis. Patients with MI-CAD from our cohort suffered greater myocardial damage compared to those with MINOCA, as demonstrated by more than 3-fold higher hs-cTnT levels and more severely depressed left-ventricular ejection fraction, strengthening the association between CRP and MACE. Still, CRP provided similar prognostic information regarding all-cause mortality in both MI types. The predictive value of CRP in MINOCA should thus, not be neglected.
| CRP (mg/dl) | <2.0 (n = 2460) | 2.0–4.9 (n = 2564) | 5.0–8.9 (n = 2419) | ≥9.0 (n = 2480) | p value | Missing values |
|------------|-----------------|-------------------|-------------------|---------------|---------|---------------|
| Risk factors | Age (years) | 66 (57–74) | 67 (58–74) | 67 (58–75) | 69 (60–76) | <.001 | - |
| | Males | 946 (38.5%) | 883 (34.4%) | 875 (36.2%) | 961 (38.8%) | .004 | - |
| | Current smoking | 375 (15.2%) | 447 (17.5%) | 439 (18.1%) | 537 (21.9%) | <.001 | 7 (0.1%) |
| | Hypertension | 1078 (43.2%) | 1159 (45.2%) | 1079 (44.6%) | 1103 (44.5%) | <.001 | 5 (0.1%) |
| | Diabetes | 262 (10.7%) | 265 (10.3%) | 270 (11.2%) | 373 (15.0%) | <.001 | - |
| | Hyperlipidemia | 496 (20.2%) | 476 (18.6%) | 438 (18.1%) | 447 (18.0%) | 0.188 | - |
| | BMI (kg/m²) | 25.4 (22.9–28.3) | 26.2 (23.8–29.4) | 26.4 (23.4–29.8) | 26.7 (23.6–30.4) | <.001 | 1229 (12.4%) |
| | eGFR (ml/min/1.73m²) | 83.1 (67.5–93.6) | 82.4 (67.4–93.1) | 82.9 (67.0–93.7) | 79.1 (61.5–92.1) | <.001 | 24 (0.2%) |
| Medical history | Heart failure | 50 (2.0%) | 54 (2.1%) | 82 (3.4%) | 108 (4.4%) | <.001 | 1 (0.0%) |
| | Previous stroke | 108 (4.4%) | 130 (5.1%) | 103 (4.3%) | 130 (5.3%) | 0.234 | 61 (0.6%) |
| | PAD | 30 (1.2%) | 42 (1.6%) | 50 (2.1%) | 83 (3.3%) | <.001 | - |
| | COPD | 150 (6.1%) | 182 (7.1%) | 224 (9.3%) | 358 (14.4%) | <.001 | - |
| | Previous/present cancer | 42 (1.7%) | 47 (1.8%) | 55 (2.3%) | 82 (3.3%) | .001 | - |
| | Dementia | 5 (0.2%) | 5 (0.2%) | 5 (0.2%) | 3 (0.1%) | 0.879 | - |
| ECG findings | Sinus rhythm | 2230 (90.8%) | 2292 (89.5%) | 2147 (89.0%) | 2077 (83.9%) | <.001 | 20 (0.2%) |
| | Atrial fibrillation | 174 (7.1%) | 209 (8.2%) | 211 (8.7%) | 310 (12.5%) | <.001 | 20 (0.2%) |
| | ST-elevation | 311 (12.7%) | 292 (11.4%) | 301 (12.5%) | 440 (17.8%) | <.001 | 26 (0.3%) |
| | ST-depression | 359 (14.6%) | 403 (15.8%) | 465 (19.3%) | 432 (17.5%) | <.001 | 26 (0.3%) |
| Medications at admission | Aspirin | 431 (17.5%) | 474 (18.5%) | 436 (18.0%) | 529 (21.3%) | .003 | - |
| | P2Y12 blockers | 60 (2.4%) | 70 (2.7%) | 53 (2.2%) | 61 (2.5%) | 0.679 | - |
| | Oral anticoagulants | 100 (4.1%) | 142 (5.5%) | 131 (5.4%) | 178 (7.2%) | <.001 | - |
| | Betablockers | 605 (24.6%) | 638 (24.9%) | 621 (25.7%) | 672 (27.1%) | 0.178 | - |
| | RAAS-inhibitors | 712 (28.9%) | 759 (29.6%) | 752 (31.1%) | 763 (30.8%) | 0.319 | - |
| | CCB | 320 (13.0%) | 312 (12.2%) | 290 (12.0%) | 219 (12.9%) | 0.625 | - |
| | Statins | 485 (19.7%) | 464 (18.1%) | 418 (17.3%) | 433 (17.5%) | 0.107 | - |
| CRP (mg/dl) | <2.0 (n = 2460) | 2.0–4.9 (n = 2564) | 5.0–8.9 (n = 2419) | ≥9.0 (n = 2480) | p value | Missing values |
|------------|-----------------|-------------------|-------------------|----------------|---------|---------------|
| Examination results |
| hs-cTnT (ng/L) | 163 (64–415) | 168 (62–462) | 182 (76–463) | 273 (108–628) | <.001 | - |
| Echocardiographic findings |
| LVEF ≥0.50 | 1643 (80.3%) | 1630 (77.7%) | 1486 (75.0%) | 1291 (63.9%) | <.001 | |
| LVEF 0.40–0.49 | 238 (11.6%) | 267 (12.7%) | 293 (14.8%) | 355 (17.6%) | |
| LVEF 0.30–0.39 | 120 (5.9%) | 141 (6.7%) | 134 (6.8%) | 260 (12.9%) | |
| LVEF <0.30 | 44 (2.2%) | 61 (2.9%) | 68 (3.4%) | 114 (5.6%) | |
| Medications at discharge |
| Aspirin | 2167 (88.4%) | 2218 (86.9%) | 2148 (89.2%) | 2077 (84.8%) | <.001 | - |
| P2Y12 blockers | 1722 (70.3%) | 1730 (67.8%) | 1662 (69.0%) | 1498 (61.1%) | <.001 | - |
| Oral anticoagulants | 180 (7.3%) | 240 (9.4%) | 205 (8.5%) | 306 (12.5%) | <.001 | 1 (0.0%) |
| Betablockers | 1927 (78.7%) | 1986 (77.9%) | 1939 (80.5%) | 1995 (81.4%) | .006 | - |
| RAAS-inhibitors | 1511 (61.7%) | 1622 (63.6%) | 1609 (66.8%) | 1611 (65.8%) | .001 | - |
| CCB | 424 (17.3%) | 442 (17.3%) | 403 (16.7%) | 376 (15.4%) | 0.199 | 1 (0.0%) |
| Statins | 2115 (86.3%) | 2165 (84.9%) | 2054 (85.3%) | 1950 (79.6%) | <.001 | - |
| Crude event rates |
| All-cause mortality | 300 (12.2%) | 374 (14.6%) | 414 (17.1%) | 768 (31.0%) | <.001 | - |
| CV mortality | 98 (4.1%) | 151 (6.1%) | 140 (5.9%) | 249 (10.3%) | <.001 | - |
| MI | 155 (6.4%) | 179 (7.2%) | 163 (6.9%) | 171 (7.1%) | 0.751 | - |
| Heart failure | 93 (3.9%) | 137 (5.5%) | 166 (7.0%) | 250 (10.3%) | <.001 | - |
| Stroke | 103 (4.3%) | 111 (4.5%) | 108 (4.6%) | 134 (5.5%) | 0.166 | - |
| MACE | 366 (15.2%) | 469 (18.8%) | 462 (19.6%) | 644 (26.6%) | <.001 | - |

Abbreviations: BMI, body mass index; CCB, calcium channel blockers; CV, cardiovascular; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; RAAS, renin-angiotensin-aldosterone system; hs-cTnT, high-sensitivity cardiac troponin T; LVEF, left-ventricular ejection fraction; MI, myocardial infarction; MACE, major cardiovascular adverse events; PAD, peripheral artery disease. Note: Data given as numbers (with percentages) or medians (with interquartile ranges).

*Follow-up data regarding all-cause mortality were available in all patients (n = 9916) until May 2018, and regarding MACE and its individual components in 9676 patients until December 2017.

b n = 4171.

cEchocardiography was performed in 8268 patients (88.3%). Data on LVEF was available in 8145 of these patients.

dAssessed in in-hospital survivors: n = 9860.
Our findings corroborate with data reported by Ciliberti et al. from a small MINOCA cohort demonstrating that CRP predicted MACE independently of the extent of coronary atheromatosis.\textsuperscript{10} This raises the question whether CRP levels might represent other disease mechanisms compared to those being relevant in MI-CAD. However, the multiple linear regressions did not reveal a clear MINOCA-specific pattern of contributing entities. Accordingly, the null hypothesis of CRP levels providing distinct clinical information in MINOCA was not rejected. In this context, it should be acknowledged that CRP levels do not necessarily reflect the proinflammatory disposition that may exist in MINOCA patients. Indirect support comes from a recent analysis from our group investigating a large array of circulating biomarkers in a stable post-MINOCA cohort.\textsuperscript{7} Here, various pro- and anti-inflammatory biomarkers other than CRP were found to discriminate MINOCA from both MI-CAD and healthy controls.

The greatest clinical value of CRP, besides prognostication, appears to lie in the distinction of true MINOCA from myocarditis mimicking MI. While cardiac magnetic resonance imaging is regarded as gold standard in this regard,\textsuperscript{1} CRP levels may guide early diagnostic work-up. CRP >10 mg/dl for example, strongly suggested the presence of myocarditis in a pooled cohort of 556 patients regarded having MINOCA.\textsuperscript{11} Likewise, CRP <5 mg/dl was shown to be associated with the presence of findings consistent with small-vessel obstruction in another study investigating 135 patients with presumed MINOCA.\textsuperscript{12} It can sometimes also be difficult to distinguish MINOCA from Takotsubo cardiomyopathy. Even in this regard, CRP may provide a clue. Takotsubo cardiomyopathy is characterized by a myocardial and systemic inflammatory reaction\textsuperscript{13} associated with an elevation in CRP levels rather seen in ST-segment elevation MI\textsuperscript{14} than in MINOCA.

Our study has several strengths. We assessed a large cohort of MINOCA patients with information on various clinically relevant outcomes. Because of the unique Swedish personal identification number and mandatory health registries, we have complete information on outcome in all patients over several years of follow-up. There are also some limitations that need to be considered. This was a retrospective investigation from a registry with inherent selection bias. Although all hospitals participating in SWEDEHEART are annually monitored, the data cannot be of the same quality as in a prospective observational study. However, the agreement between the information entered in the registry and the medical records is around 96%.\textsuperscript{15} We lack detailed information on the assays used for CRP measurements. We would not regard this as a major shortcoming since guidelines recommend the use of uniform prognostic CRP thresholds despite interassay variations in detection ranges.\textsuperscript{16} We are unable to comment on the potential associations of the severity of atheromatosis with CRP levels in MINOCA since the data available in SWEDEHEART do not allow for a subclassification of patients with coronary stenosis <50%. Moreover, we lack information on intravascular imaging which might have identified high-risk plaque morphologies contributing to higher CRP levels in some MINOCA patients. We do not have data on the

\begin{table}
\centering
\begin{tabular}{|l|c|c|c|c|c|}
\hline
 & \textbf{Model 1 (n = 9716)} & \textbf{Model 2 (n = 8061)} & \textbf{Model 3 (n = 4098)} \\
\hline
\textbf{Age (10 years)} & 0.042 & \textit{.011} & 0.025 & \textit{.070} & 0.072 & \textit{.<.001} \\
\textbf{Male sex} & 0.019 & \textit{.056} & 0.020 & \textit{.070} & 0.009 & \textit{.557} \\
\textbf{Current smoking} & 0.061 & \textit{.<.001} & 0.052 & \textit{.<.001} & 0.067 & \textit{.<.001} \\
\textbf{Hypertension} & -0.001 & 0.962 & 0.006 & 0.655 & 0.018 & 0.372 \\
\textbf{Diabetes} & 0.061 & \textit{.<.001} & 0.053 & \textit{.<.001} & 0.072 & \textit{.<.001} \\
\textbf{Hyperlipidemia} & 0.029 & 0.567 & 0.037 & 0.514 & 0.211 & \textit{.011} \\
\textbf{eGFR} & -0.075 & \textit{.<.001} & -0.053 & \textit{.<.001} & -0.033 & \textit{.070} \\
\textbf{Heart failure} & 0.025 & \textit{.016} & - & - & 0.015 & \textit{.347} \\
\textbf{Previous stroke} & 0.001 & 0.928 & -0.006 & 0.615 & -0.009 & 0.560 \\
\textbf{PAD} & 0.056 & \textit{.<.001} & 0.068 & \textit{.<.001} & 0.069 & \textit{.<.001} \\
\textbf{COPD} & 0.103 & \textit{.<.001} & 0.090 & \textit{.<.001} & 0.122 & \textit{.<.001} \\
\textbf{Previous/present cancer} & 0.030 & 0.003 & 0.030 & 0.006 & 0.046 & 0.002 \\
\textbf{Dementia} & -0.010 & 0.288 & -0.002 & 0.835 & -0.014 & 0.351 \\
\textbf{Atrial fibrillation} & 0.042 & \textit{.<.001} & 0.040 & \textit{.<.001} & 0.043 & \textit{.009} \\
\textbf{LVEF} & - & - & 0.115 & \textit{.<.001} & - & - \\
\textbf{hs-cTnT (ln)} & - & - & - & - & 0.111 & \textit{.<.001} \\
\hline
\end{tabular}
\end{table}

Abbreviations: COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left-ventricular ejection fraction; hs-cTnT: high-sensitivity cardiac troponin T; PAD, peripheral artery disease.

Note: Model 1: Analyses were adjusted for all assessed variables, medications at admission (as listed in Table 1), hospital and admission year. Model 2: adjusted as model 1 with replacement of heart failure by left-ventricular ejection fraction, categorized as \( \geq 0.50, 0.40-0.49, 0.30-0.39 \) and \(< 0.30\). Model 3: adjusted as model 1 with additional adjustment for high-sensitivity cardiac troponin T (ln).
results of examinations performed after the hospitalization period. Thus, some MINOCA patients may have subsequently been diagnosed with myocarditis, Takotsubo cardiomyopathy or any other less common diagnosis on the basis of post-discharge cardiac magnetic resonance imaging. CRP is an unspecific biomarker of inflammatory activity. SWEDHEART provides no information on infectious or non-cardiovascular inflammatory disorders that may have contributed to higher CRP levels. Finally, data on MACE were only available until December 2017.

Our results in conclusion, demonstrate that CRP is independently, albeit moderately associated with adverse outcome in MINOCA. Contrasting to our primary hypothesis, we found no evidence indicating

---

**FIGURE 1** Cumulative probability of (A) all-cause mortality and (B) major cardiovascular events in patients with myocardial infarction with nonobstructive coronary arteries (MINOCA) in relation to C-reactive protein (CRP) quartiles
that acute MINOCA might be characterized by a specific inflammatory pattern, as reflected by CRP levels.

ACKNOWLEDGMENTS
The TOTAL-AMI project has received funding from the Swedish Foundation of Strategic Research. This organization had no role in the collection, analysis and interpretation of the data, in the writing of the report and in the discussion to submit this paper for publication.

CONFLICT OF INTEREST
None of the authors reported conflicts of interest relevant to this study.

DATA AVAILABILITY STATEMENT
The data used in this study originates from the SWEDEHEART registry and contains sensitive patient information. The dataset analyzed in this study is not publicly available due to Swedish patient privacy and secrecy laws regulating access to SWEDEHEART, and due to ethical restrictions regarding the current analysis from the TOTAL-AMI project. The data used in this study originates from the SWEDEHEART registry and contains sensitive patient information. The dataset analyzed in this study is not publicly available due to Swedish patient privacy and secrecy laws regulating access to SWEDEHEART, and due to ethical restrictions regarding the current analysis from the TOTAL-AMI project (Regional Ethical Review Board in Stockholm; reference number 2012/60-31/2). We hereby confirm that other researchers are able to access the data at Uppsala Clinical Research Center upon reasonable request and under the provision that the data is accessed onsite and does not leave Uppsala University. This request can be sent to info@ucr.uu.se.

ORCID
Kai M Eggers https://orcid.org/0000-0002-8806-5778

REFERENCES
1. Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary diagnosis and Management of Patients with Myocardial Infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association. Circulation. 2019;139:e891-e908.
2. Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289-1367.
3. Thyesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction. Circulation. 2018;138:e618-e651.
4. Pasapathy S, Air T, Dreyer RP, et al. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation. 2015;131:861-870.
5. Daniel M, Ekenbäck C, Aeggelin M, et al. Risk factors and markers for acute myocardial infarction with Angiographically Normal coronary arteries. Am J Cardiol. 2015;116:838-844.
6. Safdar B, Spatz ES, Dreyer RP, et al. Presentation, clinical profile, and prognosis of young patients with myocardial infarction with non-obstructive coronary arteries (MINOCA): results from the VIRGO study. J Am Heart Assoc. 2018;7:e009174.
7. Hjort M, Eggers KM, Lindhagen L, et al. Increased inflammatory activity in patients 3 months after myocardial infarction with non-obstructive coronary arteries. Clin Chem. 2019;65:1023-1030.
8. He LP, Tang XY, Ling WH, Chen WQ, Chen YM. Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. Heart. 2010;96:339-346.
9. Krintus M, Kozinski M, Kubica J, Sypniewska G. Critical appraisal of inflammatory markers in cardiovascular risk stratification. Crit Rev Clin Lab Sci. 2014;51:263-279.
10. Ciliberti G, Coiro S, Tritto I, et al. Predictors of poor clinical outcomes in patients with acute myocardial infarction and non-obstructed coronary arteries (MINOCA). Int J Cardiol. 2018;267:41-45.
11. Tornvall P, Gerbaud E, Behagel A, et al. Myocarditis or “true” infarction by cardiac magnetic resonance in patients with a clinical diagnosis of myocardial infarction without obstructive coronary disease: a meta-analysis of individual patient data. Atherosclerosis. 2015;241:87-91.
12. Lamour A, Caramzana A, Gráni C, et al. Is an ischemic origin in MINOCA patients predictable? Int J Cardiovasc Imaging. 2020;36:2251-2253.
13. Ciutac AM, Dawson D. The role of inflammation in stress cardiomyopathy. *Trends Cardiovasc Med*. 2021;31:225-230.
14. Madhavan M, Borlaug BA, Lerman A, Rihal CS, Prasad A. Stress hormone and circulating biomarker profile of apical ballooning syndrome (Takotsubo cardiomyopathy): insights into the clinical significance of B-type natriuretic peptide and troponin levels. *Heart*. 2009;95:1436-1441.
15. Jernberg T, Attebring MF, Hambraeus K, et al. The Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). *Heart*. 2010;96:1617-1621.
16. Algarra M, Gomes D, Esteves da Silva JC. Current analytical strategies for C-reactive protein quantification in blood. *Clin Chim Acta*. 2013;415:1-9.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Eggers KM, Baron T, Hjort M, Nordenskjöld AM, Tornvall P, Lindahl B. Clinical and prognostic implications of C-reactive protein levels in myocardial infarction with nonobstructive coronary arteries. *Clin Cardiol*. 2021;44(7):1019–1027. [https://doi.org/10.1002/clc.23651](https://doi.org/10.1002/clc.23651)